在KRAS突变癌症中,RASH3D19通过正反循环调解RAS激活
Warapen Treekitkarnmongkol1, Hiroshi Katayama2, Deivendran Sankaran1,3
1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nature cell biology
|December 1, 2025
概括
研究人员确定RASH3D19是癌细胞生长和抗KRAS抑制剂的关键调解剂. 准RASH3D19可能会克服抗药性,并缩小KRAS突变癌症中的瘤.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 积极调查突变KRAS驱动癌症的治疗点.
- 确定反机制驱动适应性抵抗KRAS抑制剂.
研究的目的:
- 确定RASH3D19作为RAS通路激活的调解者.
- 调查RASH3D19在KRAS突变癌症耐药性中的作用.
主要方法:
- 研究了KRAS-microRNA信号轴.研究了KRAS-microRNA信号轴.
- 检查了RASH3D19在RAS通路激活和反循环中的作用.
- 评估了RASH3D19遗传删除在体外和体内的影响.
主要成果:
- 确定了RASH3D19作为一个积极反循环中的调解者,涉及KRAS-microRNA信号传输.
- 证明RASH3D19通过EGFR复杂相互作用促进RAS通路的激活.
- 对RASH3D19的遗传删除抑制了癌细胞的生长,并使细胞对KRAS抑制剂敏感.
结论:
- RASH3D19是RAS通路的重新激活和适应性抵抗的关键调解者.
- 针对RASH3D19提供了一种潜在的策略,以克服对KRAS抑制剂的耐药性.
- 抑制RASH3D19可能导致KRAS突变癌症的瘤脱.
相关概念视频
The Ras Gene
7.0K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
7.0K
Small GTPases - Ras and Rho
5.2K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
5.2K
MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K


